- Conditions
- Infection, Bone Neoplasms
- Interventions
- 24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen
- Drug
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 7,881
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Failure, Surgery, Renal Failure
- Interventions
- Information provision
- Other
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Ann Arbor, Michigan + 3 more
- Conditions
- Leukemia
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 200
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 148 more
- Conditions
- Non-segmental Vitiligo
- Interventions
- Ruxolitinib cream, Vehicle
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Fremont, California • Irvine, California + 24 more
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
- Interventions
- Gemcitabine, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 919 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 51 more
- Conditions
- Adolescent Obesity
- Interventions
- Standard Care, Simple Scale, EHR-Connected Scale
- Other · Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Interventions
- 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 9,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2065
- U.S. locations
- 484
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more
- Conditions
- Coronary Artery Disease
- Interventions
- Prevail DCB, Agent DCB
- Device
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 48 more
- Conditions
- Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
- Interventions
- Anti TNF therapy including infliximab, No Biologics
- Biological · Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 4,970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2038
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 28 more
- Conditions
- Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- Orasi Medical, Inc.
- Industry
- Eligibility
- 20 Years to 92 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Plymouth, Minnesota
- Conditions
- Wide Neck Bifurcation Intracranial Aneurysms
- Interventions
- WEB
- Device
- Lead sponsor
- Microvention-Terumo, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 29
- States / cities
- Hollywood, Florida • Orlando, Florida • Honolulu, Hawaii + 22 more
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 108
- States / cities
- Burbank, California • Palo Alto, California • San Diego, California + 75 more
- Conditions
- Cryptogenic Stroke
- Interventions
- AMPLATZER PFO Occluder, Standard of Care - Medical Management
- Device · Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more
- Conditions
- Exercise, Physical Activity, Accidental Fall, Motivation, Older Adults
- Interventions
- Otago Exercise Program, Physical activity monitors (e.g., Fitbit), Interpersonal Behavior Change Strategies, Intrapersonal Behavior Change Strategies, Information about Health and Wellness
- Behavioral · Device · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Symptomatic Apical Periodontitis, Postoperative Pain, Mechanical Allodynia
- Interventions
- Adjunctive Photobiomodulation, Sham Photobiomodulation
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Heart Failure, CKD Stage 3
- Interventions
- AquaPass System
- Device
- Lead sponsor
- AquaPass Medical Ltd.
- Industry
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Francisco, California • Minneapolis, Minnesota + 5 more
- Conditions
- Pain
- Interventions
- 150% Oral Morphine Equivalent (OME), Clinical Judgment
- Drug · Other
- Lead sponsor
- Allina Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Allogeneic HCT Survivors
- Interventions
- 10 Weeks of Strength Trailing, Group Nutrition Discussion: week 1, week 5 and week 10
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1,116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 282
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Auburn, California + 200 more
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Ramelteon
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 119 more
- Conditions
- Fragile X Syndrome, Fragile X Syndrome (FXS)
- Interventions
- ZYN002, Placebo
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Culver City, California • Irvine, California + 15 more
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Interventions
- canakinumab (anti IL-1beta), Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
- Conditions
- Parkinson Disease
- Interventions
- NS 2330
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 47
- States / cities
- Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more